Considering testosterone cypionate? It’s one of the most popular testosterone esters, but understanding proper use, dosing, and risks is essential before first injection.

You’ve heard testosterone cypionate is the standard for TRT and cycles. You’re considering using it.

But you’re unclear on what makes cypionate different from other testosterone esters, how to dose it properly, and what side effects to expect.

You’ve been told:

• “Cypionate is the best testosterone ester”
• “Just inject once weekly and you’re good”
• “Side effects are minimal with testosterone”
• “It’s the safest steroid”

Some of this is true, but oversimplified. The truth: Testosterone cypionate is a long-acting ester (8-12 day half-life) of synthetic testosterone that requires 1-2x weekly injections, takes 4-6 weeks to reach steady-state levels, and is widely used for both TRT (100-200mg/week) and performance enhancement (200-600mg/week). While testosterone is relatively mild compared to harsher steroids, supraphysiological doses still cause side effects: acne, hair loss, gynecomastia, water retention, elevated hematocrit, cholesterol disruption, cardiovascular stress, and testosterone suppression. The severity depends on dose, duration, and individual genetics.

In this comprehensive guide, I’ll explain what testosterone cypionate is (the ester and pharmacokinetics), reveal typical cycle protocols (dosing, duration, frequency for different goals), detail all common side effects (mechanisms, likelihood, prevention, reversibility), compare to other testosterone esters (cypionate vs. enanthate vs. propionate), and provide safety guidelines (monitoring, harm reduction, PCT).

Whether you’re considering TRT or performance enhancement, understanding testosterone cypionate completely is essential.

Let’s examine testosterone cypionate scientifically and practically.

What Is Testosterone Cypionate?

The compound explained.

The Basic Definition

What it is:

• Synthetic version of testosterone hormone
• Injectable formulation
• Testosterone molecule + cypionate ester attached
• Exogenous testosterone

What it’s not:

• Not “stronger” or “weaker” than other testosterone esters
• Not a different hormone (just different delivery)
• Not superior to enanthate or other long esters (functionally equivalent)
• Same hormone, different ester

The purpose:

• Medical: Treat hypogonadism (low testosterone)
• Performance: Muscle building, strength gains, physique enhancement
• Dual applications

The Cypionate Ester

What the ester does:

• Ester = chemical chain attached to testosterone
• Acts as time-release mechanism
• Determines absorption rate and half-life
• Pharmacokinetic modifier

The cypionate ester specifically:

• 8-carbon chain
• Similar length to enanthate (7-carbon)
• Longer than propionate (3-carbon)
• Shorter than decanoate (10-carbon)
• Medium-long ester

How it works:

• After injection, sits in muscle tissue (depot)
• Enzymes called “esterases” break bond
• Free testosterone gradually released into bloodstream
• Controlled release

The half-life:

• Approximately 8-12 days
• Some sources say 10-12, others 7-8 (individual variation)
• Functionally very similar to enanthate (7-10 days)
• Extended duration

Testosterone Cypionate vs. Other Esters

The testosterone molecule:

• Identical across all esters
• Cypionate, enanthate, propionate = same testosterone
• Only difference is ester (delivery speed)
• Same active hormone

The ester comparison:

Testosterone cypionate:

• Half-life: 8-12 days
• Injection frequency: 1-2x weekly
• Onset: Gradual (4-6 weeks to steady state)
• Long-acting

Testosterone enanthate:

• Half-life: 7-10 days
• Injection frequency: 1-2x weekly
• Onset: Gradual (4-6 weeks to steady state)
• Virtually identical to cypionate

Testosterone propionate:

• Half-life: 1-2 days
• Injection frequency: Daily or EOD
• Onset: Rapid (days to peak)
• Short-acting

Testosterone undecanoate:

• Half-life: 20-30 days
• Injection frequency: Every 10-14 days
• Onset: Very gradual (weeks to steady state)
• Very long-acting

The verdict:

• Cypionate and enanthate are interchangeable
• Propionate for those wanting control (daily injections)
• Undecanoate for maximum convenience (rare)
• Choose based on injection frequency preference

Regional Preferences

United States:

• Testosterone cypionate is standard
• Most commonly prescribed for TRT
• Most available in UGL market
• US preference

Europe and elsewhere:

• Testosterone enanthate more common
• Pharmaceutical availability differs
• Functionally equivalent
• Regional variation

The reason:

• Historical pharmaceutical production patterns
• No pharmacological superiority either way
• Arbitrary geographical preference

Typical Testosterone Cypionate Cycles

Dosing protocols for different goals.

Important Disclaimer

No “official” dosing exists:

• Medical TRT dosing established (100-200mg/week)
• Performance dosing NOT medically sanctioned
• Recreational use doses based on empirical evidence (user reports, not clinical trials)
• Anecdotal protocols

The gray area:

• TRT doses: Medical supervision, proven safety
• Supraphysiological doses: No medical oversight, increased risks
• Risk escalation

TRT (Testosterone Replacement Therapy)

The medical context:

• For men with clinically low testosterone (<300 ng/dL)
• Goal: Restore to normal physiological range (400-800 ng/dL)
• Medical supervision required
• Therapeutic use

Typical TRT protocol:

• Dose: 100-200mg per week total
• Frequency: Split into 2 doses weekly (50-100mg each) or weekly single dose
• Duration: Indefinite (long-term therapy)
• Monitoring: Regular bloodwork (testosterone, estradiol, hematocrit, PSA, lipids)
• Replacement dosing

The example:

• 100mg Monday, 100mg Thursday = 200mg/week total
• Maintains steady levels in normal range
• Standard TRT

Beginner Cycle (First Steroid Use)

The approach:

• Testosterone-only cycle (no other compounds)
• Learn individual response
• Establish baseline
• Solo testosterone

Typical beginner protocol:

• Dose: 300-500mg per week
• Frequency: Split into 2 doses weekly (150-250mg each)
• Duration: 8-12 weeks
• Conservative cycle

The example:

• 250mg Monday, 250mg Thursday = 500mg/week
• 12-week duration
• Classic first cycle

Why this dosing:

• Sufficient for significant gains
• Not excessive (risk management)
• Allows assessment of aromatization (estrogen conversion)
• Learning cycle

Intermediate Cycle

The context:

• Multiple cycles completed
• Understand personal response
• May stack with other compounds
• Experience required

Typical intermediate protocol:

• Dose: 400-600mg per week (testosterone alone) or 200-400mg/week (if stacking)
• Frequency: 2x weekly
• Duration: 10-16 weeks
• Standard protocol

The example (testosterone-only):

• 300mg Monday, 300mg Thursday = 600mg/week
• 12-week duration
• Higher dose solo

The example (stacked):

• 250mg testosterone Monday, 250mg Thursday = 500mg/week
• Plus other compound (e.g., 400mg nandrolone weekly)
• Stacked protocol

Advanced Cycle (Not Recommended)

The context:

• Years of experience
• Professional bodybuilders
• High risk
• Extreme use

Typical advanced protocol:

• Dose: 600-1000mg+ per week
• Often stacked with multiple other compounds
• Duration: 12-20+ weeks (sometimes year-round “blasting and cruising”)
• High-risk approach

The health cost:

• Severe side effects
• Long-term organ damage
• Dependency
• Not advisable

Injection Frequency

The options:

Once weekly:

• Convenient
• More fluctuation between doses
• Example: 500mg every Monday
• Acceptable but suboptimal

Twice weekly (preferred):

• More stable blood levels
• Less fluctuation
• Better results and fewer sides
• Example: 250mg Monday, 250mg Thursday
• Optimal approach

The comparison:

• Once weekly: Peak 2-3 days post-injection, trough day 6-7 (larger fluctuation)
• Twice weekly: Minimal fluctuation (more stable)
• Twice weekly superior

Bulking vs. Cutting

Bulking (muscle gain):

• Higher doses (400-600mg/week)
• Caloric surplus
• Primary goal: Maximize muscle growth
• Accept some water retention
• Mass building

Cutting (fat loss):

• Lower doses (200-400mg/week)
• Caloric deficit
• Primary goal: Preserve muscle while losing fat
• May add AI to reduce water retention
• Preservation

The versatility:

• Testosterone works for both goals
• Dose and diet determine outcome
• Flexible application

Side Effects of Testosterone Cypionate

What to expect at supraphysiological doses.

Side Effect 1: Acne

The mechanism:

• Testosterone (and DHT) stimulate sebaceous glands
• Increased sebum (oil) production
• Excess oil clogs pores
• Bacteria proliferate, inflammation occurs
• Androgenic skin effect

Likelihood:

• Dose-dependent (higher dose = more likely)
• Genetic predisposition determines severity
• History of acne = higher risk
• Variable

Prevention:

• Good hygiene (shower after training)
• Topical treatments (benzoyl peroxide, salicylic acid)
• Oral antibiotics (if severe)
• Management strategies

Reversibility:

• Resolves after cessation
• May leave scars if severe/untreated
• Temporary problem

Side Effect 2: Hair Loss (Androgenic Alopecia)

The mechanism:

• Testosterone converts to DHT (dihydrotestosterone)
• DHT binds to scalp follicle receptors
• Miniaturizes follicles (if genetically prone)
• Progressive hair thinning and loss
• DHT-mediated

Likelihood:

• Only in genetically predisposed individuals (MPB genes)
• Family history of baldness = high risk
• No family history = low risk
• Genetic lottery

Prevention:

• Finasteride or dutasteride (5α-reductase inhibitors)
• Block testosterone → DHT conversion
• Partially effective (reduces but doesn’t eliminate)
• Limited prevention

Reversibility:

• Dead follicles don’t regenerate
• Lost hair = permanent
• Stopping progression possible by ceasing use
• Irreversible

Side Effect 3: Gynecomastia (Gyno)

The mechanism:

• Supraphysiological testosterone levels
• Enzyme aromatase converts excess testosterone to estradiol (estrogen)
• Elevated estrogen stimulates breast tissue growth
• Aromatization pathway

Likelihood:

• Dose-dependent (higher dose = more aromatization)
• Individual aromatase activity varies
• 500mg/week: Moderate risk
• 1000mg/week: High risk
• Common at high doses

Prevention:

• Aromatase inhibitors (AIs): Anastrozole, exemestane
• Block testosterone → estrogen conversion
• Dose AI based on bloodwork (don’t crash estrogen)
• Preventable with AI

Early intervention:

• SERMs (Nolvadex, raloxifene) if lumps detected early
• Can reverse early-stage gyno (small lumps)
• Time-sensitive

Reversibility:

• Early stage: Reversible with SERMs
• Established (>3 months, large lumps): Surgery only
• Partially reversible

Side Effect 4: Water Retention

The mechanism:

• Testosterone (and estrogen) affect kidney function
• Alter sodium reabsorption
• Increased sodium = increased water retention
• Elevated blood volume
• Renal effect

The consequences:

• “Puffy” appearance (face, abs)
• Increased blood pressure (volume expansion)
• Weight gain (water weight)
• Cosmetic and health impact

Likelihood:

• Common at moderate-high doses
• Estrogen-related (aromatization contributes)
• Frequent

Management:

• AI to reduce estrogen (reduces retention)
• Moderate sodium intake (<3000mg daily)
• Adequate hydration paradoxically helps
• Controllable

Reversibility:

• Water weight drops within 1-2 weeks after cessation
• Blood pressure normalizes
• Fully reversible

Side Effect 5: Elevated Hematocrit

The mechanism:

• Testosterone stimulates erythropoiesis (red blood cell production)
• Increases RBC count
• Elevates hematocrit percentage
• Blood becomes more viscous (thicker)
• Hematological effect

The risk:

• Thick blood strains heart
• Increased clotting risk
• Stroke and heart attack risk elevated
• Cardiovascular danger

Likelihood:

• Common, especially at doses >300mg/week
• Genetic variation in response
• Frequent

The numbers:

• Normal hematocrit: 38-50%
• On testosterone: Can reach 52-55%+
• 54% = clinical concern
• Elevation common

Management:

• Donate blood (reduces RBC count)
• Stay hydrated
• Monitor bloodwork
• Reduce dose if excessive
• Bloodwork essential

Reversibility:

• Normalizes weeks after cessation
• Reversible

Side Effect 6: Cholesterol Disruption

The mechanism:

• Supraphysiological androgens alter liver enzyme function
• Hepatic lipase activity increases
• HDL (good cholesterol) catabolism accelerated
• LDL (bad cholesterol) accumulates
• Hepatic lipid metabolism disruption

The changes:

• HDL drops 20-40%
• LDL increases 10-30%
• Total cholesterol ratio worsens
• Atherogenic profile

Likelihood:

• Universal at supraphysiological doses
• Degree varies individually
• Inevitable

Prevention:

• Diet: High fiber, omega-3s, minimize saturated fat
• Cardio: 150+ min weekly
• Supplements: Fish oil, plant sterols
• Cannot fully prevent, only minimize
• Damage control

Reversibility:

• Normalizes 2-6 months after cessation
• Mostly reversible

Side Effect 7: Cardiovascular System Stress

The mechanisms:

1. Left ventricular hypertrophy:

• Testosterone directly causes heart muscle thickening
• Reduces cardiac efficiency
• Structural change

2. Hypertension:

• Water retention increases blood volume
• Elevated hematocrit increases viscosity
• Combined effect raises blood pressure
• Pressure elevation

3. Atherosclerosis acceleration:

• Poor lipid profile promotes plaque formation
• Arterial stiffening
• Vascular damage

The cumulative risk:

• Heart attack risk elevated
• Stroke risk elevated
• Heart failure risk long-term
• Serious health threat

Likelihood:

• Dose and duration dependent
• All users experience some degree
• Long-term use = significant damage
• High probability

Management:

• Cardiovascular exercise (essential)
• Blood pressure monitoring
• Lipid management
• Lower doses, shorter cycles
• Risk mitigation

Reversibility:

• Blood pressure: Usually reverses
• Lipids: Normalize 2-6 months
• LVH: Partially reverses (some permanent)
• Arterial damage: Partially reversible
• Mixed outcomes

Side Effect 8: Testosterone Suppression

The mechanism:

• Exogenous testosterone detected by brain
• Hypothalamic-pituitary-testicular (HPT) axis shuts down
• LH and FSH production cease
• Testes stop producing testosterone
• Negative feedback loop

The timeline:

• Suppression begins within days
• Complete shutdown within 2-4 weeks
• Testicular atrophy (shrinkage) over months
• Rapid onset

Likelihood:

• 100% of users experience suppression
• Degree: Near-complete shutdown common
• Universal effect

Post-cycle consequences:

• Crash: Low testosterone after cycle (if no PCT)
• Symptoms: Fatigue, depression, muscle loss, fat gain, low libido
• Hypogonadal state

Recovery:

• With PCT: 4-8 weeks typically
• Without PCT: 6-12+ months (natural recovery)
• Rare cases: Permanent suppression (require TRT for life)
• Usually reversible with PCT

Prevention of suppression:

• Impossible while using testosterone
• Unavoidable

Side Effect 9: Virilization in Women

The mechanism:

• Women have much lower natural testosterone
• Any exogenous testosterone causes masculinization
• Androgen receptors throughout body activated
• Masculinizing effects

The effects:

• Voice deepening (permanent)
• Clitoral enlargement (permanent)
• Facial/body hair growth (permanent)
• Male pattern baldness (permanent)
• Menstrual irregularities or cessation
• Irreversible changes

Likelihood:

• Occurs even at low doses (10-25mg/week)
• Higher doses = faster and more severe
• Inevitable with continued use

Reversibility:

• Voice changes: Permanent
• Clitoral growth: Permanent
• Hair growth: Permanent (though can be managed cosmetically)
• Menstrual cycle: May recover after cessation
• Mostly irreversible

The recommendation:

• Women should avoid testosterone (use anavar, primobolan instead if considering steroids)
• Risk-benefit extremely unfavorable
• Not advisable for women

Post-Cycle Therapy (PCT)

Recovering natural testosterone production.

Why PCT Is Essential

The problem:

• Testosterone suppression during cycle
• After last injection, exogenous test declining
• Natural production still shut down
• The crash

Without PCT:

• 6-12+ months low testosterone
• Severe symptoms (fatigue, depression, muscle loss)
• May not fully recover (rare but possible)
• Miserable recovery

With PCT:

• 4-8 weeks to recovery
• Faster restoration of natural production
• Preserves muscle gains better
• Accelerated recovery

PCT Timing for Testosterone Cypionate

The guideline:

• Wait 2 weeks after last injection
• Then begin PCT
• 14-day wait

Why wait:

• 8-12 day half-life
• After 2 weeks (1.5-2 half-lives), levels low enough
• Starting PCT earlier = ineffective (still suppressed)
• Clearance period

Standard PCT Protocol

The protocol:

• Clomid: 50mg daily for 4-6 weeks
• Nolvadex: 20mg daily for 4-6 weeks
• Often used together
• SERM therapy

Alternative protocols:

• Clomid only: 50mg daily for 6 weeks
• Nolvadex only: 40mg daily for 2 weeks, then 20mg daily for 2-4 weeks
• HCG (during cycle or bridge to PCT): 250-500 IU 2-3x weekly
• Variations exist

The mechanism:

• SERMs block estrogen receptors in pituitary
• Stimulates LH and FSH release
• LH signals testes to produce testosterone
• Natural production restarted

Monitoring Recovery

Bloodwork:

• 4-6 weeks post-PCT
• Check total testosterone, LH, FSH, estradiol
• Verify recovery
• Objective assessment

The target:

• Testosterone back in normal range (400+ ng/dL)
• LH and FSH in normal range
• Recovery confirmation

If not recovered:

• Extend PCT
• Consider HCG protocol
• Medical consultation
• Further intervention

Safety and Harm Reduction

Minimizing risks.

Essential Monitoring

Pre-cycle bloodwork:

• Total testosterone, free testosterone
• Estradiol
• LH, FSH
• Lipid panel (HDL, LDL, triglycerides)
• Liver enzymes (AST, ALT)
• Kidney function (creatinine, eGFR)
• CBC (complete blood count, check hematocrit)
• Baseline established

Mid-cycle bloodwork (6-8 weeks in):

• Total testosterone (verify dose)
• Estradiol (adjust AI if needed)
• Hematocrit (check if elevated)
• On-cycle monitoring

Post-cycle bloodwork (4-6 weeks after PCT):

• Same panel as pre-cycle
• Verify recovery
• Recovery confirmation

The frequency:

• Minimum: Pre, mid, post
• Optimal: Pre, weeks 4 & 8, post
• Regular assessment

Dosing Guidelines

For health:

• Lower doses = fewer side effects
• 300-500mg/week: Meaningful gains, manageable sides
• 600mg+/week: Diminishing returns, escalating sides
• Dose restraint

For longevity:

• Shorter cycles (8-12 weeks)
• Time off equals time on (minimum)
• Don’t blast and cruise indefinitely
• Cycling approach

Ancillary Medications

Aromatase inhibitor (AI):

• Anastrozole: 0.5mg 2x weekly starting dose
• Adjust based on bloodwork
• Goal: Estradiol in 20-30 pg/mL range
• Don’t crash estrogen (<10 pg/mL = problems)
• Estrogen management

When to use AI:

• Gyno symptoms (sensitivity, lumps)
• Excessive water retention
• High blood pressure from retention
• Bloodwork shows high estradiol
• Symptom or lab-driven

Blood pressure medication (if needed):

• ARBs (telmisartan, losartan)
• ACE inhibitors
• Medical supervision
• Hypertension control

Lifestyle Optimization

Cardiovascular exercise:

• 150+ minutes weekly minimum
• Essential for heart health
• Improves lipids slightly
• Non-negotiable

Diet:

• High fiber
• Omega-3 fatty acids
• Minimize saturated fats
• Moderate sodium
• Heart-healthy nutrition

Avoid compounding risks:

• Don’t smoke
• Limit alcohol
• Manage stress
• Adequate sleep
• Risk reduction

---

This article is informational only. We do not condone or recommend steroid use. If considering any hormone therapy, work with qualified medical professionals and understand the serious health risks involved.

REFERENCES

SECTION 1 — Pharmacokinetics and ester mechanism

[1] Shoskes JJ et al. — PMC/Translational Andrology and Urology, 2016 Review of testosterone replacement therapy preparations; unmodified testosterone has ~10 min half-life when injected; esterification at C17β prolongs duration of action by increasing lipid solubility; testosterone cypionate has an 8-carbon side chain (vs. 7-carbon for enanthate); ester group is cleaved by esterases before testosterone becomes biologically active; cypionate and enanthate functionally interchangeable but differ in carrier oil (cypionate uses olive oil, enanthate uses sesame oil); both require 1-2x weekly injections for optimal level stability https://pmc.ncbi.nlm.nih.gov/articles/PMC5182226/

[2] Pastuszak AW et al. — PMC/Andrology, 2022 Comprehensive pharmacokinetics review; IM testosterone cypionate produces supraphysiological levels within 1 week of administration; large peak-to-trough fluctuations occur with weekly dosing; Endocrine Society guideline recommends measuring levels midway between injections; testosterone levels with IM testosterone cypionate approximately 700 ng/dL at 100mg/week, 1100 ng/dL at 250mg/week, and 2000 ng/dL at 500mg/week https://pmc.ncbi.nlm.nih.gov/articles/PMC9293229/

---

SECTION 2 — TRT medical dosing context

[3] Leslie SW & Bhatt C — NCBI StatPearls, 2023 Androgen replacement clinical review; testosterone cypionate and enanthate are FDA-approved for hypogonadism; initial doses typically 100mg weekly to minimize supernormal peak levels; weekly injections optimal to minimize supraphysiological peaks; testosterone in plasma 98% protein-bound; cypionate and enanthate used almost interchangeably in clinical practice; normal testosterone range established as 300–1000 ng/dL https://www.ncbi.nlm.nih.gov/books/NBK534853/

---

SECTION 3 — Cardiovascular side effects of supraphysiological testosterone

[4] Frankenfeld SP et al. — PMC/Frontiers in Physiology, 2020 Study on supraphysiological testosterone and vascular dysfunction; supraphysiological testosterone linked to increased blood pressure, left ventricular hypertrophy, vascular dysfunction, and elevated inflammatory markers; testosterone propionate at supraphysiological doses induced vascular dysfunction via mitochondrial ROS generation and NLRP3 inflammasome activation; physiological testosterone promotes vasodilation while supraphysiological doses shift toward pathological cardiovascular effects https://pmc.ncbi.nlm.nih.gov/articles/PMC7411079/

[5] Freitas M et al. — American Journal of Physiology, 2023 Review of testosterone cardiovascular effects; supraphysiological testosterone associated with harmful cardiovascular outcomes including increased blood pressure, endothelial dysfunction, arterial stiffness, dyslipidemia, and elevated hematocrit; testosterone gender-affirming therapy for 12 months increased hematocrit from 40.8% to 45.8% (p<0.001) and decreased HDL-C by 19.6%; erythrocytosis is the most frequent adverse event associated with testosterone therapy in randomized trials; hematocrit should be kept below 54% https://journals.physiology.org/doi/full/10.1152/ajpheart.00015.2023

[6] Ruige JB & Ouwens DM — PMC/Cardiovascular Risk and Testosterone, 2021 Review of cardiovascular risk and testosterone; testosterone-induced erythrocytosis is dose-dependent and age-influenced; clinical guidance recommends hematocrit monitoring at 3–4 months and annually; hematocrit must be kept below 54% during testosterone treatment; testosterone also associated with increased platelet aggregation and thromboxane A2 concentrations; HDL cholesterol functional capacity (cholesterol efflux) shown to decrease with testosterone therapy https://pmc.ncbi.nlm.nih.gov/articles/PMC8087565/

---

SECTION 4 — Cholesterol and lipid disruption

[7] Saad F et al. — PMC/Steroids, 2015 Review of testosterone and HDL in men; substantial decreases in HDL-C mainly demonstrated with supraphysiological doses of androgens in young men and with anabolic androgen use in athletes; HDL-lowering effect variable with age, dose, and route of administration; most striking with high-dose oral therapy; testosterone-induced suppression of HDL-C associated with upregulation of hepatic lipase and suppression of apolipoprotein A1; TRT at physiological replacement doses shows less marked effect on lipids than supraphysiological doses https://pmc.ncbi.nlm.nih.gov/articles/PMC4527564/

---

SECTION 5 — Testosterone suppression and HPG axis

[8] de Ronde W & Smit DL — PMC/Endocrine Connections, 2023 Scoping review of recovery from AAS-induced hypogonadism; exogenous testosterone augments HPG axis negative feedback, suppressing GnRH, LH, and FSH; HPG axis recovery in most cases with under 1 year AAS use occurs within 1 year of cessation; spontaneous recovery occurs within 6–12 months; PCT with clomiphene citrate (CC) and/or hCG facilitates earlier hormonal normalization; CC + hCG superior to monotherapy for recovery of semen parameters and testicular volume; HPG axis response varies greatly among individuals https://pmc.ncbi.nlm.nih.gov/articles/PMC10620455/

---

SECTION 6 — PCT mechanism and evidence

[9] Grant CNJ et al. — PMC/Substance Abuse Treatment, Prevention, and Policy, 2023 Survey of 470 AAS users; PCT typically involves hCG combined with SERMs and/or aromatase inhibitors; hCG directly stimulates Leydig cell testosterone production; SERMs and AIs indirectly stimulate LH-mediated testosterone production by reducing estrogenic negative feedback on HPG axis; self-administered PCT associated with 60% reduction in craving and withdrawal symptoms; PCT use associated with reduced withdrawal symptoms compared to cessation without intervention https://pmc.ncbi.nlm.nih.gov/articles/PMC10640727/